Phase
Condition
Pancreatic Cancer
Adenocarcinoma
Pancreatic Disorders
Treatment
Cyclophosphamide
Urelumab
Nivolumab
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Newly diagnosed or clinically-suspected adenocarcinoma of the head, neck, oruncinate process of the pancreas
Tumor must be surgically resectable
ECOG Performance Status of 0 to 1
Adequate organ function as defined by study-specified laboratory tests
Must agree to use acceptable form of birth control
Exclusion
Exclusion Criteria:
Received any type of anti-cancer treatment or immunotherapy for pancreas cancer
History of autoimmune disease (Graves or Hashimoto's disease, vitiligo, and type Idiabetes are allowed)
Systemically steroid use within 14 days
Evidence of active infection
Pregnant or lactating
Diagnosed with another cancer or myeloproliferative disorder (some exceptions)
History of severe hypersensitivity reaction to any monoclonal antibody or knowncomponent of the study drugs
Known history of infection with HIV, hepatitis B, or hepatitis C
Oxygen saturation of <92% on room air by pulse oximetry
On home oxygen
Study Design
Study Description
Connect with a study center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland 21231-2410
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.